Literature DB >> 2155736

Mechanism of action of 5-aminosalicylic acid and its derivatives.

A Ireland1, D P Jewell.   

Abstract

The mechanism of action of 5-ASA and its derivatives remains obscure. The most likely mechanisms would appear to be an interrelationship between local production of eicosanoids and reactive oxygen metabolites, in conjunction with activated neutrophils, though the nature of the initial triggering factor/s remains to be determined. The possibility that bacterial-derived chemotactic peptides, such as FMLP, might be a triggering factor is an attractive possibility, made possible by an underlying defect in mucosal permeability.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155736     DOI: 10.1042/cs0780119

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  10 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 2.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

3.  Inflammatory bowel disease--a radical view.

Authors:  N J Simmonds; D S Rampton
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

4.  Optimum dose of olsalazine for maintaining remission in ulcerative colitis.

Authors:  S P Travis; C Tysk; H J de Silva; H Sandberg-Gertzén; D P Jewell; G Järnerot
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

Review 5.  Clinical pharmacokinetics of slow release mesalazine.

Authors:  M De Vos
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

6.  The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis.

Authors:  M C Pitcher; E R Beatty; J H Cummings
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

7.  Experience with the use of salazosulfapyridine for intractable diarrhea after hematopoietic stem cell transplantation.

Authors:  Naohiko Moriguchi; Sadayuki Isokawa; Atsushi Ando; Hiroshi Miyata
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

8.  Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.

Authors:  B Crotty; W M Rosenberg; J K Aronson; D P Jewell
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

9.  Salicylates used in inflammatory bowel disease and colchicine impair interferon-gamma induced HLA-DR expression.

Authors:  B Crotty; P Hoang; H R Dalton; D P Jewell
Journal:  Gut       Date:  1992-01       Impact factor: 23.059

10.  Azathioprine, Mercaptopurine, and 5-Aminosalicylic Acid Affect the Growth of IBD-Associated Campylobacter Species and Other Enteric Microbes.

Authors:  Fang Liu; Rena Ma; Stephen M Riordan; Michael C Grimm; Lu Liu; Yiming Wang; Li Zhang
Journal:  Front Microbiol       Date:  2017-03-29       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.